## 3 Results  
After carrying out the search, 491 articles were found. Of these, 183 articles were identified in PubMed/MEDLINE, 171 in Scopus, 65 in Web of Science, and 72 articles in DOAJ. Then, the articles that were duplicated (n = 214) were eliminated, which resulted in 277 studies. After analyzing the title and abstract, another 260 articles were excluded. Then, a total of 17 articles remained for full-text reading. After performing the full reading, four more articles were excluded due to lack of information and detail on the patient follow up. Thus, 13 articles were included in this systematic review (10 case reports, 2 retrospective studies, and 1 prospective study). The agreements between reviewers were, for initial assessment, k = 0.97 and, for assessment of the final inclusion, k = 0.91 (Figure 1). The demographic data for the patients/implants and studies included are summarized in Tables 3 and 4. A total of 67 patients were analyzed and 163 dental implants were placed in the studies included. All of them were Caucasian, with a mean age of 62 years old (58 female and 9 male). The mean follow-up period was 28.9 months (ranging from 12 months to 48 months). The risk factors reported were hypertension, tobacco, poor oral hygiene, and diabetes, and all of these factors were respectively linked to higher implant  
\begin{table} \begin{tabular}{c c c} \hline \hline
**Database** & **Equation Implemented** & **Filters** \\ \hline Pubmed/ MEDLINE & ((((((((((((((((((((((((((((((((((((((((( ( ( ( ( (                                                                                \\ \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ \hline \hline \end{tabular} 
\begin{tabular}{c}  
failure rates of 8%, 19%, 2%, and 7%. Most of the diseases for which BPs were taken were osteoporosis, multiple myeloma, breast cancer, lung cancer, prostate cancer, knee cancer, and osteogenesis imperfecta. The routes of BP administration were oral and intravenous. A total of 42 patients (63%) were on therapy with BPs administered orally, and 25 patients (37%) received BPs through IV. For oral administration, the drugs were Alendronate [14, 17, 18, 19, 20, 21, 22], Risedronate [16, 17, 21], and Ibandronate [14, 17, 19], whereas those administered intravenously were Zoledronate [14, 17, 19, 22, 23, 24, 25, 26], Clodronate [27], and Pamidronate [14, 19, 26]. The duration of the use of BPs at the time of implant placement was diverse. It varied from no interruption of BP intake to its discontinuation from 2, 3, or for 6 months before surgery, with respective resumption 1, 3, or 8 months after surgery. Antibiotic treatment (amoxicillin + clav  
Figure 1: Article selection strategy, according to the PRISMA Flowchart (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). before the intervention in two cases and before and after surgical treatment in three cases. Use only after intervention was not found. Antibiotic treatment proved to be effective in cases where it was used as a pre- and post-surgical therapy. Finally, a percentage of implant survival in the group taking BPs had an average failure rate of 42.27%. Four studies did not have any implant failure [15; 16; 22; 24]. The most prevalent BPs corresponded to the second generation (Alendronate and Pamidronate), which were used in 61% of the cases, followed by the third generation (Zoledronate, Ibandronate, and Risedronate), which were found in 38% of the cases; only one case utilized first generation BPs (Clodronate). Regarding this variable, a lower failure rate was noted when patients used the second-generation BPs (37%), followed by third generation (38%) and first generation (100%). Moreover, when patients discontinued BP therapy (45% of the cases), lower failure rates were obtained than patients with continuous use (55%). The quality assessment of the study was considered to be of low/moderate level, with all studies excepting [PERSON] et al. presenting values between 2 and 5 (Figure 2).